bioFILM PA™
is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.

Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.

Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 4,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA™ test.

bioFILM PA™ has gained marketing approval in Israel.

 

 

bioFilm PA™ prelaunch experimental test:

LevPharm and Innovotech have performed a clinical experimental test in all 6 CF medical centers in Israel.

In order to validate the results a double check of the specimans was done both in Israel labs and Canada (Innovotech's lab).

The results were analized  and the recommended antibiotic combinations that came out of the trial will be implemented in all 13 CF patients. The results are the union of MIC and MBEC tests.

Presentation at the annual meeting of the Israeli Society of Microbiology 2012

First lecture on the first day of the ISM meeting was dedicated to the bioFILM PA™
kit as a new assay for antimicrobial susceptibility testing of Pseudomoans Aeroginosa Biofilms in Cystic Fibrosis patients.
The lecture was led by Ms. N. Belausov from Clinical Microbiology Lab, Sheba Medical Center and Dr. Yuval Geffen head of Clinical Microbiology Lab, Rambam Medical Center.
The lecture's conclusion was that the assay supports the feasibility of adapting bioflim susceptibility testing method to the microbiology laboratory and would help to select more effective antibiotic therapy for clinical use.
The presentors and the audience shared the feeling that more clinical practice is required.

LevPharm Ltd has signed an agreement with OssDsign to represent it in Israel and markets its products in the NeuroSurgery field  

 Lev Pharm ltd.  10 Levinson str. Petah-Tikva 49401 Israel     Tel: +972-3-9230851   Fax:  +972-3-9245074